Prolia and Xgeva QT Interval Heart Injury

Drug Liability Attorneys in New York City

Prolia and Xgeva (active ingredient denosumab), a drug manufactured by
Amgen, is used to combat osteoporosis. Women receive injections every
six months. Denosumab is known to cause a sudden decrease in a patient's
calcium level (hypocalcaemia) and doctors are expected to use it with
great care in patients with a preexisting calcium deficiency. Recent reports
now link the hypocalcaemia to conditions which may lead to sudden death.

At Rheingold Giuffra Ruffo & Plotkin LLP, lead attorney Paul Rheingold
led out firm's successful litigation against Janssen and Johnson &
Johnson for the Propulsid QT Interval litigation after the drug was removed
from the market in 2000. If you or someone you know has suffered from
Prolia or Xgeva, our team has the experience and resources to help.

Contact us today online or by telephone at
(888) 260-0473to speak with a knowledgeable New York defective drug lawyer. Our firm
handles a case from start to finish.

Adverse Effects from Hypocalcemia

In August 2016, new warnings were added to Prolia and Xgeva by the Australian
Government Therapeutic Goods Administration. Side effect reports showed
that serum calcium levels became so low that the following side effects occurred:

QT interval prolongation leading to cardiac arrest and sudden death

Tetany

Seizures

Altered mental status

What is a QT Interval Prolongation?

In cardiology, the QT interval is a measure of the time between the start
of the Q wave and the end of the T wave in the heart's electrical
cycle. The QT interval represents electrical depolarization and repolarization
of the ventricles. Calcium ions pass back and forth across cell membrane
and generate the electrical activity (depolarization and repolarization)
that initiates the heart's mechanical function. A rapid depletion
of calcium from the use of Prolia and Xgeva can lead to serious side effects.
That is why the Australian Government Therapeutic Goods Administration
has demanded stronger warnings.

Client Focused Litigation

This is not a class action where you are piled in with other victims and
given a token settlement or coupon! Your case is personal to you. All
decisions are made with you and only you. Many drug product liability
cases evolve into two choices: participate in a settlement plan or litigating
to a trial. The choice is yours and no one forces you into one option
or another. Settlement plans often provide significant recoveries without
the delays and expenses associated with trials.

Whether the litigation has settlements or trials, the drug companies will
be forced to answer for what has been done. In drug product litigation,
pharmaceutical companies are forced to turn over millions of internal
documents which reveal what happened and why. This work sometimes gets
the Department of Justice to levy fines. In certain very egregious cases,
the FBI has even sought to investigate criminal issues. A wave of litigation
and trial verdicts forces corporate boards to "face the music"
with shareholders and Wall Street.

Have you or someone close to you been harmed by Prolia or Invega? Please
contact us at
(888) 260-0473 to speak to an experienced New York dangerous drugs liability attorney.
Our law office is conveniently located in a brownstone in Midtown Manhattan
located at 113 East 37th Street.

The information on this website is for general information purposes only.
Nothing on this site should be taken as legal advice for any individual
case or situation. This information is not intended to create, and receipt
or viewing does not constitute, an attorney-client relationship.

x

⚠

Your browser is out of date. To get the full experience of this website,
please update to most recent version.